Oral vs. Vaginal Misoprostol: Which is Better for Labor Induction?

Labor induction is a common procedure for pregnant women who are at or beyond 41 weeks gestation. Misoprostol, a prostaglandin E1 analog, is widely used for this purpose due to its ability to soften the cervix and stimulate uterine contractions. However, the optimal route of administration (oral vs. vaginal) for misoprostol in nulliparous women (those who have not given birth before) remains a subject of debate regarding efficacy and safety.

As this is a recently registered clinical trial (NCT05696574) with an estimated completion date of June 2023, the specific findings are not yet published. The study is designed to compare several key outcomes between the oral and vaginal Misoprostol groups. Researchers aim to assess the time from induction to delivery, the rate of successful vaginal delivery within 24 hours, and the need for additional interventions such as oxytocin augmentation or cesarean section. They will also monitor maternal and neonatal adverse events, including uterine hyperstimulation, fetal distress, and infection rates. The primary objective is to determine if one route of Misoprostol administration offers a statistically significant advantage in terms of efficacy (e.g., shorter labor duration) or safety profile for nulliparous women undergoing labor induction, with results anticipated post-completion.